The Advisory Committee on Immunization Practices voted Wednesday to recommend lowering the age at which adults can get a ...

The good news is that most cases of whooping cough are preventable with DTaP vaccines in childhood and Tdap shots at age 11 ...

A key group of government advisers voted to expand the use of vaccines for a common respiratory illness, providing a boost to ...

A federal panel of experts on Wednesday recommended an expansion of RSV vaccinations for adults and a new combination shot as ...

The U.S. Centers for Disease Control and Prevention's panel of outside experts on Wednesday recommended the use of ...

The U.S. Centers for Disease Control and Prevention's outside panel of vaccine experts on Tuesday discussed narrowing ...

People are being urged to take influenza and other respiratory diseases seriously and get vaccinated before cold weather ...

GSK and Pfiz­er have set­tled a law­suit al­leg­ing Pfiz­er’s RSV shot Abrys­vo in­fringed GSK’s patents.

As the respiratory syncytial virus (RSV) vaccine field grapples with a significantly reduced market size thanks to regulatory uncertainties, GSK and Pfizer have decided to lay to rest their patent ...

especially in infants and older adults. The patent battle over RSV vaccines highlights intensifying competition in the global vaccine market. Despite dropping this particular case, legal tensions ...

(Reuters) -British pharmaceutical giant GlaxoSmithKline (NYSE:GSK) and rival Pfizer (NYSE:PFE) have agreed to end a lawsuit that alleged Pfizer’s respiratory syncytial virus (RSV) vaccine ...